What is Cytokinetics's stock-based comp?

Cytokinetics (CYTK) reported stock-based comp of $30.39M in Q1 2026.

How has Cytokinetics's stock-based comp changed year-over-year?

Cytokinetics's stock-based comp increased by 29.1% year-over-year, from $23.55M to $30.39M.

What is the long-term trend for Cytokinetics's stock-based comp?

Over 4 years (2021 to 2025), Cytokinetics's stock-based comp has grown at a 43.0% compound annual growth rate (CAGR), from $26.83M to $112.29M.

Cytokinetics CYTK Stock-Based Comp

Stock-Based Comp at other companies

BioMarin PharmaceuticalsBMRN

——

MedtronicMDT

——

Other financials

Income statement

See full

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

See full

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

See full

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

See full

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

See full

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

See full

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytokinetics's stock-based comp?: Cytokinetics (CYTK) reported stock-based comp of $30.39M in Q1 2026.
How has Cytokinetics's stock-based comp changed year-over-year?: Cytokinetics's stock-based comp increased by 29.1% year-over-year, from $23.55M to $30.39M.
What is the long-term trend for Cytokinetics's stock-based comp?: Over 4 years (2021 to 2025), Cytokinetics's stock-based comp has grown at a 43.0% compound annual growth rate (CAGR), from $26.83M to $112.29M.